Alzamend Neuro issues 300,000 shares on conversion of Series B Preferred Stock

Alzamend Neuro, Inc.

Issued 300,000 common shares upon conversion of 696 Series B Preferred shares between Sep 17-25, 2025.
Common shares outstanding as of Sep 25, 2025: 3,439,861.
Shares issued in reliance on Section 4(a)(2) exemption; no registration.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Alzamend Neuro, Inc. issued 300,000 shares of common stock of common stock to Series B Convertible Preferred Stock holders for conversion of 696 shares of Series B Convertible Preferred Stock.

Security: common stock
Shares: 300,000 shares of common stock
Purchaser: Series B Convertible Preferred Stock holders
Consideration: conversion of 696 shares of Series B Convertible Preferred Stock

Exact text from the filing

Between September 17, 2025 and September 25, 2025, Alzamend Neuro, Inc. (the “ Company ”) issued an aggregate of 300,000 shares of common stock, par value $0.0001 per share (“ Common Stock ”) upon conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock.

View on SEC.gov

Browse all equity issuances →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-25-014200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.